JP2014510122A5 - - Google Patents

Download PDF

Info

Publication number
JP2014510122A5
JP2014510122A5 JP2014503105A JP2014503105A JP2014510122A5 JP 2014510122 A5 JP2014510122 A5 JP 2014510122A5 JP 2014503105 A JP2014503105 A JP 2014503105A JP 2014503105 A JP2014503105 A JP 2014503105A JP 2014510122 A5 JP2014510122 A5 JP 2014510122A5
Authority
JP
Japan
Prior art keywords
phenyl
pyrrolo
dihydro
methylmorpholino
urea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014503105A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014510122A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/055953 external-priority patent/WO2012136622A1/en
Publication of JP2014510122A publication Critical patent/JP2014510122A/ja
Publication of JP2014510122A5 publication Critical patent/JP2014510122A5/ja
Pending legal-status Critical Current

Links

JP2014503105A 2011-04-04 2012-04-02 ｍＴＯＲ阻害剤としてのジヒドロピロロピリミジン誘導体 Pending JP2014510122A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11160983.0 2011-04-04
EP11160983 2011-04-04
PCT/EP2012/055953 WO2012136622A1 (en) 2011-04-04 2012-04-02 Dihydropyrrolo pyrimidine derivatives as mtor inhibitors

Publications (2)

Publication Number Publication Date
JP2014510122A JP2014510122A (ja) 2014-04-24
JP2014510122A5 true JP2014510122A5 (enExample) 2015-05-21

Family

ID=44246546

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014503105A Pending JP2014510122A (ja) 2011-04-04 2012-04-02 ｍＴＯＲ阻害剤としてのジヒドロピロロピリミジン誘導体

Country Status (4)

Country Link
US (1) US20140163023A1 (enExample)
EP (1) EP2694511A1 (enExample)
JP (1) JP2014510122A (enExample)
WO (1) WO2012136622A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9249129B2 (en) 2010-03-04 2016-02-02 Cellzome Limited Morpholino substituted urea derivatives as mTOR inhibitors
KR20140070616A (ko) 2011-09-21 2014-06-10 셀좀 리미티드 Mtor 저해제로서의 모르폴리노 치환된 우레아 또는 카바메이트 유도체
BR112014008241A2 (pt) 2011-10-07 2017-04-18 Cellzome Ltd composto, composição farmacêutica, métodos para tratar, controlar, retardar ou prevenir doenças e distúrbios, e para preparar um composto, e, uso de um composto
NZ718487A (en) 2013-10-16 2020-01-31 Shanghai Yingli Pharm Co Ltd Fused heterocyclic compound, preparation method therefor, pharmaceutical composition, and uses thereof
EP3478686B1 (en) * 2016-06-29 2020-04-15 H. Hoffnabb-La Roche Ag Novel dihydropyrrolopyrimidines for the treatment and prophylaxis of hepatitis b virus infection
EP3849535A4 (en) 2018-09-10 2022-06-29 Mirati Therapeutics, Inc. Combination therapies
CN111606926B (zh) * 2020-05-13 2021-10-15 大连理工大学 一种苯并咪唑[1,3]氮硫杂卓类化合物的制备方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0961780T3 (da) 1997-02-12 2007-08-27 Electrophoretics Ltd Proteinmarkörer for lungecancer og anvendelse deraf
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
JP3893026B2 (ja) 1999-02-10 2007-03-14 アストラゼネカ アクチボラグ 血管形成阻害剤としてのキナゾリン誘導体
ES2306306T3 (es) 1999-11-05 2008-11-01 Astrazeneca Ab Nuevos derivados de quinazolina.
DK1255752T3 (da) 2000-02-15 2007-11-26 Sugen Inc Pyrrolsubstituerede 2-indolinonproteinkinaseinhibitorer
US7135298B2 (en) 2003-03-26 2006-11-14 The Burnham Institute For Medical Research Screening assay for agents that alter target of Rapamycin activity
EP1887359B1 (en) 2006-08-03 2008-11-12 Cellzome Ag Methods for the identification of PI3K interacting molecules and for the purification of PI3K
CA2660758A1 (en) 2006-08-24 2008-02-27 Astrazeneca Ab Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
US20080234262A1 (en) 2007-03-21 2008-09-25 Wyeth Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
US20080233127A1 (en) 2007-03-21 2008-09-25 Wyeth Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors
EP2178563A2 (en) 2007-07-06 2010-04-28 OSI Pharmaceuticals, Inc. Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mtorc2
ATE554075T1 (de) 2007-07-09 2012-05-15 Astrazeneca Ab Bei mit mtor-kinase und/oder pi3k in zusammenhang stehenden krankheiten angewendete morpholinopyrimidinderivate
WO2009007749A2 (en) 2007-07-09 2009-01-15 Astrazeneca Ab Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
AR067478A1 (es) 2007-07-09 2009-10-14 Astrazeneca Ab Compuestos derivados de morfolina pirimidina
WO2009007751A2 (en) 2007-07-09 2009-01-15 Astrazeneca Ab Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
US20110009403A1 (en) * 2007-10-05 2011-01-13 S*Bio Pte Ltd. 2-morpholinylpurines as inhibitors of pi3k
CN101224207A (zh) 2007-10-12 2008-07-23 中国科学院上海有机化学研究所 具有诱导自吞噬治疗错误折叠蛋白聚集所致疾病的药物及其筛选方法
ATE528408T1 (de) 2008-02-04 2011-10-15 Cellzome Ag Selektivitätsprofilerstellung von mit pi3k wechselwirkenden molekülen gegen mehrere ziele
EP2307414A4 (en) 2008-07-07 2011-10-26 Xcovery Holding Co Llc SELECTIVE INHIBITORS OF PI3 KINASE ISOFORMS
WO2010014939A1 (en) 2008-07-31 2010-02-04 Genentech, Inc. Pyrimidine compounds, compositions and methods of use
US8829011B2 (en) * 2008-10-29 2014-09-09 Janssen Pharmaceutica Nv 2-aminopyrimidine compounds as serotonin receptor modulators
ES2539478T3 (es) 2008-11-11 2015-07-01 Xcovery Holding Company Llc Inhibidores de PI3K/mTOR cinasa
EP2406258B1 (en) 2009-03-13 2014-12-03 Cellzome Limited PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2010120994A2 (en) 2009-04-17 2010-10-21 Wyeth Llc Ureidoaryl-and carbamoylaryl-morpholino- pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis
WO2010120991A1 (en) 2009-04-17 2010-10-21 Wyeth Llc 5, 6, 7, 8-tetrahydropyrido[4,3-d]pyrimidine compounds, their use as mtor, pi3, and hsmg-1 kinase inhibitors, and their syntheses
WO2010120996A1 (en) * 2009-04-17 2010-10-21 Wyeth Llc 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
WO2010120998A1 (en) * 2009-04-17 2010-10-21 Wyeth Llc Pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
WO2010120987A1 (en) 2009-04-17 2010-10-21 Wyeth Llc Ring fused, ureidoaryl- and carbamoylaryl-bridged morpholino-pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
WO2011011716A1 (en) 2009-07-23 2011-01-27 The Trustees Of Princeton University Inhibitors of mtor kinase as anti-viral agents
US9249129B2 (en) 2010-03-04 2016-02-02 Cellzome Limited Morpholino substituted urea derivatives as mTOR inhibitors

Similar Documents

Publication Publication Date Title
JP2014510122A5 (enExample)
JP6218260B2 (ja) Ｊａｋ阻害剤としてのアミノピリミジニル化合物
JP5808793B2 (ja) キナーゼ調節のための化合物および方法、ならびにそれらの適応症
RU2019115115A (ru) Производные пиперидина в качестве ингибиторов убиквитин-специфической протеазы 7
JP6192839B2 (ja) ピロロ［２，３−ｄ］ピリミジニル、ピロロ［２，３−ｂ］ピラジニル、およびピロロ［２，３−ｄ］ピリジニルアクリルアミド
JP2019535664A5 (enExample)
FI3932919T3 (fi) Jak-inhibiittoriyhdiste ja sen käyttö
RU2014115476A (ru) Производные пиразоло[4, 3-с]птридина в качестве ингибиторов киназ
JP2020510010A5 (enExample)
JP2014531449A5 (enExample)
JP2014530197A5 (enExample)
US20110262407A1 (en) Treatment with alpha7 selective ligands
RU2015121374A (ru) Ингибиторы alk-киназы
RU2010116759A (ru) Пиримидиновые производные, используемые в качестве ингибиторов протеинкиназы
RU2014109748A (ru) Морфолино-замещенные производные бициклических пиримидинмочевины или карбамата в качестве ингибиторов mtor
RU2000110738A (ru) Бициклические ингибиторы киназ
JP2012501312A5 (enExample)
RU2014128307A (ru) Пиррольное производное шестичленного гетероарильного кольца, способ его получения и его медицинское применение
JP2012526736A5 (enExample)
RU2010117156A (ru) Гетероциклические соединения в качестве антагонистов crth2 рецептора
EA023824B1 (ru) ПРОИЗВОДНЫЕ 3,4-ДИГИДРОПИРРОЛО[1,2-a]ПИРАЗИН-1-ИЛАМИНА, ПРИГОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ БЕТА-СЕКРЕТАЗЫ (BACE)
JP2014528436A5 (enExample)
RU2009123930A (ru) Химические соединения 637: пиридопиримидиндионы в качестве ингибиторов pde4
RU2010148534A (ru) Производные имидазолидинона в качестве ингибиторов в 11b-hsd1
RU2014126750A (ru) Ингибиторы тирозинкиназы брутона